Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: urban (3), residential (24), industrial (50)

Cyclophosphamide-Doxorubicin Ver 1.1

Description: Regimen Chemotherapy Protocol BREAST CANCER CYCLOPHOSPHAMIDE-DOXORUBICIN Breast Cancer – Cyclophosphamide-Doxorubicin Indication Primary systemic (neoadjuvant) th
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Cyclophosphamide-Doxorubicin-Ver-1.1.pdf

Cyclophosphamide-Docetaxel-Epirubicin (100)-Fluorouracil (FE100CT)

Description: Chemotherapy Protocol BREAST CANCER CYCLOPHOSPHAMIDE-DOCETAXEL-EPIRUBICIN (100)- FLUOROURACIL Regimen (FE100CT) • Breast Cancer – Cyclophosphamide-Docetaxel-Epiru
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Cyclophosphamide-Docetaxel-Epirubicin-100-Fluorouracil.pdf

Head injury - patient information

Description: This factsheet contains information that you and your family or carers may find useful after your head injury.
Url: /Media/UHS-website-2019/Patientinformation/Generalmedicine/Headinjury-1709-PIL.pdf

Steroid treatment for premature babies - patient information

Description: Steroid treatment for premature babies Information for patients, parents and guardians We have given you this information leaflet b
Url: /Media/UHS-website-2019/Patientinformation/Childhealth/Steroid-treatment-for-premature-babies-2127-PIL.pdf

Pembrolizumab(400mg)

Description: Chemotherapy Protocol COLORECTAL CANCER Pembrolizumab (400mg) Regimen • Colorectal – Pembrolizumab (400mg) Indication • Pembrolizumab is recommen
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Colorectal/Pembrolizumab400mg.pdf

Dr Helena Lee, associate director for emerging therapies

Description: Auto Generated Title Email: Helena.Lee@uhs.nhs.uk Dr Lee is an MRC Clinician Scientist Fellow and Associate Professor in
Url: /ClinicalResearchinSouthampton/Our-people/Clinical-research-facility-people/Dr-Helena-Lee-associate-director-for-emerging-therapies.aspx

Ready Steady Go: Transition plan - patient information

Description: Transition programme DATE SECTION NUMBER PROGRESS NOTES/GOALS Transition programme NOTES Transition programme Name: Address:
Url: /Media/UHS-website-2019/Patientinformation/Childhealth/ReadySteadyGo/Ready-Steady-Go-Transition-plan.pdf

Hello to adult services: Transition plan - patient information

Description: Ready Steady Go Transition Programme DATE SECTION NUMBER PROGRESS NOTES/GOALS Ready Steady Go Transition Programme NOTES Ready Steady Go
Url: /Media/UHS-website-2019/Patientinformation/Childhealth/Hello/Hello-to-adult-services-Transition-plan.pdf

Cetuximab-Irinotecan (21day)

Description: Chemotherapy Protocol COLORECTAL CANCER CETUXIMAB-IRINOTECAN (21 day) This regimen may require funding Regimen • Colorectal Cancer–Cetuxi
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Colorectal/Cetuximab-Irinotecan.pdf

Cetuximab (500)-Fluorouracil-Folinic Acid-Irinotecan

Description: Chemotherapy Protocol COLORECTAL CANCER CETUXIMAB(500)-FLUOROURACIL-FOLINIC ACID (Modified de Gramont)IRINOTECAN Regimen This regimen may require
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Colorectal/Cetuximab500-Fluorouracil-FolinicAcid-Irinotecan.pdf

461 to 470 of 1000

Previous … 45 46 47 48 49 … Next